Cargando…

High‐Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta‐Adrenoceptor Blockade: A Randomized Clinical Trial

BACKGROUND: Intravenous high‐dose glucagon is a recommended antidote against beta‐blocker poisonings, but clinical effects are unclear. We therefore investigated hemodynamic effects and safety of high‐dose glucagon with and without concomitant beta‐blockade. METHODS AND RESULTS: In a randomized cros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petersen, Kasper M., Bøgevig, Søren, Riis, Troels, Andersson, Niklas W., Dalhoff, Kim P., Holst, Jens J., Knop, Filip K., Faber, Jens, Petersen, Tonny S., Christensen, Mikkel B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763418/ https://www.ncbi.nlm.nih.gov/pubmed/33103603 http://dx.doi.org/10.1161/JAHA.120.016828

Ejemplares similares

Outcomes following calcium channel blocker exposures reported to a poison information center
por: Christensen, Mikkel B., et al.
Publicado: (2018)

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
por: Christensen, Mikkel, et al.
Publicado: (2011)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Glucagon Receptor Signaling and Lipid Metabolism
por: Galsgaard, Katrine D., et al.
Publicado: (2019)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
por: Subramanian, Vijaya, et al.
Publicado: (2022)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
por: Christensen, Mikkel B, et al.
Publicado: (2020)

Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
por: Holst, Jens Juul
Publicado: (2022)

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
por: Hædersdal, Sofie, et al.
Publicado: (2020)

Methods and Guidelines for Measurement of Glucagon in Plasma
por: Holst, Jens J., et al.
Publicado: (2019)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
por: Hare, Kristine J., et al.
Publicado: (2010)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014)

Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study
por: Hansen, Nina L., et al.
Publicado: (2020)

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
por: Ørgaard, Anne, et al.
Publicado: (2017)

Postprandial Insulin Secretion After Gastric Bypass Surgery: The Role of Glucagon-Like Peptide 1
por: Holst, Jens Juul
Publicado: (2011)

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
por: Vilsbøll, Tina, et al.
Publicado: (2012)

Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study
por: Gade, Christina, et al.
Publicado: (2018)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Neutrophil β(1) adrenoceptor blockade blunts stroke‐associated neuroinflammation
por: Clemente‐Moragón, Agustín, et al.
Publicado: (2022)

Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males
por: Skov, Jeppe, et al.
Publicado: (2014)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

General Practitioners’ Barriers Toward Medication Reviews in Polymedicated Multimorbid Patients: How can a Focus on the Pharmacotherapy in an Outpatient Clinic Support GPs?
por: Laursen, Jannie, et al.
Publicado: (2018)

Methodological Considerations for Describing Medication Changes in Relation to Clinical Events and Death: An Applied Example in Patients with Type 2 Diabetes and Cancer
por: Johansson, Karl Sebastian, et al.
Publicado: (2023)

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes: Systematic review and meta-analysis of clinical studies
por: Calanna, Salvatore, et al.
Publicado: (2013)

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes
por: Sonne, David P, et al.
Publicado: (2014)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

Treatment of subclinical hyperthyroidism: effect on left ventricular mass and function of the heart using magnetic resonance imaging technique
por: Mark, Peter D, et al.
Publicado: (2015)

Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies
por: Petersen, Karen Ekkelund, et al.
Publicado: (2016)

Insulin and Glucagon: Partners for Life
por: Holst, Jens Juul, et al.
Publicado: (2017)

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
por: Foghsgaard, Signe, et al.
Publicado: (2013)

Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls
por: Andersen, Andreas, et al.
Publicado: (2021)

β-Adrenoceptor blockade modulates fusiform gyrus activity to black versus white faces
por: Terbeck, S., et al.
Publicado: (2015)

β(2)-Adrenoceptor Blockade Deteriorates Systemic Anaphylaxis by Enhancing Hyperpermeability in Anesthetized Mice
por: Yang, Wei, et al.
Publicado: (2018)

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
por: Nauck, Michael A., et al.
Publicado: (2011)

Impact of β-Adrenoceptor Blockade on Systemic Inflammation and Coagulation Disturbances in Rats with Acute Traumatic Coagulopathy
por: Xu, Lin, et al.
Publicado: (2015)

Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
por: Asmar, Ali, et al.
Publicado: (2017)

Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study
por: Idorn, Thomas, et al.
Publicado: (2013)

Resistance training affects the hemodynamic parameters of hypertensive and normotensive women differently, and regardless of performance improvement
por: De Sá, Clodoaldo Antônio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pdn1gj2pnh1db5a6989urfcjcq